ruxolitinib + venetoclax

**Ruxolitinib + venetoclax** is an investigational combination of two small molecule drugs: ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, and venetoclax, a selective BCL-2 inhibitor. The combination is currently being studied for the treatment of various hematologic malignancies, particularly in patients with relapsed or refractory disease such as acute myeloid leukemia (AML) and T-cell prolymphocytic leukemia (T-PLL), including cases with JAK-STAT pathway alterations[1][3][4][7]. Ruxolitinib works by inhibiting JAK1/2-mediated signaling involved in cell growth and inflammatory cytokine production, while venetoclax disrupts the anti-apoptotic BCL-2 protein, promoting programmed cell death in malignant cells. Preclinical and early clinical data suggest synergistic effects by targeting parallel survival pathways, enabling disease control even in patients ineligible for stem cell transplantation[1][4][7]. The combination is being used primarily in clinical trials and case series; its safety profile is considered manageable with potential risks for cytopenias and infections[3][7]. Primary developers and marketers of the individual components are Novartis/Incyte for ruxolitinib and AbbVie/Genentech for venetoclax.